Le Lézard
Classified in: Health
Subjects: SVY, TRI

Kaiser Permanente Study Finds Cognitive Behavioral Therapy Is Cost-Effective for Teens Who Decline Antidepressants


PORTLAND, Ore., Jan. 19, 2018 /PRNewswire/ -- Cognitive behavioral therapy (or CBT) delivered in a primary care setting is a cost-effective way to treat adolescents with depression who decline or quickly stop using antidepressants, according to a Kaiser Permanente study published today in the journal Pediatrics.

Kaiser Permanente Logo. (PRNewsFoto/Kaiser Permanente)

This work builds upon previous research, also published in Pediatrics, showing that CBT improved time to diagnostic recovery from major depression for teenagers who received CBT in their primary care clinic. Participants who received CBT learned how to modify their behaviors, challenge their unrealistic and negative beliefs, and think more positively.

Depression is a widespread and costly health problem in the U.S., with one estimate placing the total economic burden of depression at more than $210 billion annually. Among adolescents, the prevalence of depression is on the rise. Antidepressant medications are the usual course of treatment for adolescents diagnosed with depression, but as many as half of families with a depressed child choose not to begin antidepressant therapy. And among those who do begin treatment, nearly half do not continue, for reasons including side effects, lack of benefit and cost.

"Untreated or undertreated depression is a serious burden for many adolescents and their families, and the impact is often felt for many years after diagnosis," said John Dickerson, PhD, a health economist at the Kaiser Permanente Center for Health Research and lead author of the new publication. "Now we have evidence that CBT is not only clinically effective, but cost-effective as well. This is good news for patients, their families and health care systems."

In their new analysis, the study team showed that over a two-year period, depression-related health care costs for adolescents who received CBT were about $5,000 less on average than depressed adolescents in the control group, who received usual care without CBT.

Researchers examined depression-related costs from a societal perspective, meaning they accounted for costs experienced by patients and their families in addition to the costs borne by the health care system. In addition to the cost of delivering the CBT intervention to patients, researchers examined the cost of mental health-related inpatient hospital stays, a wide variety of medical and mental health services, and the time that parents spent taking their children to services, among other factors.

The study, which included 212 adolescents who received care in Kaiser Permanente primary care clinics in Oregon and Washington, showed that a CBT intervention can be brief and still deliver long-term benefits in terms of cost and clinical outcomes.

"Most other studies of CBT for depressed youths that we looked at involved a much longer treatment program than the one we tested," Dickerson explained. "We chose to test a 'lean' model with a smaller number of CBT sessions because such a model is more likely to be adopted by health care organizations. It's important for health systems and families to know that a brief CBT program is likely to improve mental health outcomes for depressed adolescents who decline antidepressants, and is also likely to be cost-effective over time."

The study was funded by a grant from the National Institutes of Mental Health (R01-MH73918) and was led by Greg Clarke, PhD, of the Kaiser Permanente Center for Health Research.

Additional authors include Frances Lynch, PhD, Michael Leo, PhD, John Pearson, MD, and Greg Clarke, PhD, from the Kaiser Permanente Center for Health Research in Portland, Ore.; and Lynn DeBar, PhD, from the Kaiser Permanente Health Research Institute in Seattle.

About the Kaiser Permanente Center for Health Research
The Kaiser Permanente Center for Health Research, founded in 1964, is a nonprofit research institution dedicated to advancing knowledge to improve health. It has research sites in Portland, Oregon, and Honolulu. Visit kpchr.org for more information.

About Kaiser Permanente
Kaiser Permanente is committed to helping shape the future of health care. We are recognized as one of America's leading health care providers and not-for-profit health plans. Founded in 1945, Kaiser Permanente has a mission to provide high-quality, affordable health care services and to improve the health of our members and the communities we serve. We currently serve more than 11.7 million members in eight states and the District of Columbia. Care for members and patients is focused on their total health and guided by their personal Permanente Medical Group physicians, specialists and team of caregivers. Our expert and caring medical teams are empowered and supported by industry-leading technology advances and tools for health promotion, disease prevention, state-of-the-art care delivery and world-class chronic disease management. Kaiser Permanente is dedicated to care innovations, clinical research, health education and the support of community health. For more information, go to: kp.org/share.

For more information, contact:
Jonathan Fine, [email protected], 503-528-3997
Heather Platisha, [email protected], 415-262-5992

 

SOURCE Kaiser Permanente


These press releases may also interest you

at 04:00
Cancer spreads from its primary tumor to other parts of the body via blood or the lymphatic system in a process termed 'metastasis'. This usually represents an advanced stage in the disease's progression and tends to be fatal. Therefore, preventing...

at 03:30
Vicore Pharma Holding (STO:VICO)Sessions at ATS to include an oral late-breaking presentation of the final results from the Phase 2a AIR trial of buloxibutid (C21) in IPFAdditional presentations include preclinical and translational data reflecting...

at 03:13
Orexo's Annual and Sustainability Report for 2023 has been published and can be downloaded at, www.orexo.com. The Swedish version of the Report is also available on the company's website in European Single Electronic Format (ESEF). A PDF version is...

at 03:05
Surge has just closed its second round of funding, raising ?7.5 million. The round was led by Eurazeo with the participation of Kima, Teampact, and MH Innov', as well as the support of historical funds Boutique Venture, HCVC, and 50 Partners Santé....

at 03:00
CSL Vifor is pleased that its partner Akebia Therapeutics, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved Vafseo (vadadustat) tablets for the treatment of anemia due to chronic kidney disease (CKD) in adults who...

at 03:00
An analysis by the World Wildlife Fund (WWF) suggests that the average person ingests as many as 5 grams of microplastics weekly ? that's the equivalent of eating a whole credit card. While the exact effects of plastics on human health are still...



News published on and distributed by: